Benzinga | Jun 2, 2021 08:04AM EDT

Genmab And Bolt Biotherapeutics Announce Oncology Research And Development Collaboration; Bolt To Receive $10M Upfront Payment And $15M Equity Investment From Genmab

Genmab A/S (NASDAQ:GMAB) and Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced today that the companies have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt's proprietary Boltbody(tm) immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for the treatment of cancer. This research collaboration will evaluate multiple bispecific ISAC concepts to identify up to three clinical candidates for development. Genmab will fund the research, along with the preclinical and clinical development of these candidates through clinical proof of concept.